CP107

CP107 is a long-acting injectable formulation of octreotide, a synthetic cyclic octapeptide and somatostatin analog, being developed by Consegna Pharma. The drug utilizes a proprietary delivery technology to provide a sustained release over a 90-day period, significantly extending the dosing interval compared to standard long-acting formulations. CP107 acts as an agonist at somatostatin receptors, particularly SSTR2 and SSTR5, which leads to the inhibition of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) secretion, as well as the suppression of various gastrointestinal and pancreatic hormones. It is currently in preclinical development for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors.

Other names

octreotideOctreotide 90-dayOctreotide90-dayOctreotide-90-dayOctreotide LAI